Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist

V. Ubertini, G. Norelli, D. D'Arcangelo, A. Gurtner, E. Cesareo, S. Baldari, M. P. Gentileschi, G. Piaggio, P. Nisticò, S. Soddu, A. Facchiano, G. Bossi

Research output: Contribution to journalArticle

Abstract

The TP53 tumor-suppressor gene is frequently mutated in human cancer. Missense mutations can add novel functions (gain-of-function, GOF) that promote tumor malignancy. Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN). We show that mutp53 but not wild-type (wt) p53 suppresses the sIL-1Ra production in conditioned media of cancer cells. Moreover, mutp53, but not wtp53, binds physically the sIL-1Ra promoter and the protein-protein interaction with the transcriptional co-repressor MAFF (v-MAF musculoaponeurotic fibrosarcoma oncogene family, protein F) is required for mutp53-induced sIL-1Ra suppression. Remarkably, when exposed to IL-1 beta (IL-1β) inflammatory stimuli, mutp53 sustains a ready-to-be-activated in vitro and in vivo cancer cells' response through the sIL-1Ra repression. Taken together, these results identify sIL-1Ra as a novel mutp53 target gene, whose suppression might be required to generate a chronic pro-inflammatory tumor microenvironment through which mutp53 promotes tumor malignancy.

Original languageEnglish
Pages (from-to)2493-2504
Number of pages12
JournalOncogene
Volume34
Issue number19
DOIs
Publication statusPublished - May 7 2015

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics
  • Medicine(all)

Fingerprint Dive into the research topics of 'Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist'. Together they form a unique fingerprint.

Cite this